VIVUS (NASDAQ:VVUS) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday, September 12th.
Separately, Zacks Investment Research raised shares of VIVUS from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Wednesday, May 16th.
Shares of VVUS stock traded down $0.05 on Wednesday, hitting $4.34. 65,839 shares of the company’s stock traded hands, compared to its average volume of 91,005. The company has a debt-to-equity ratio of -10.60, a quick ratio of 4.26 and a current ratio of 4.93. VIVUS has a one year low of $3.30 and a one year high of $9.90. The firm has a market cap of $46.98 million, a P/E ratio of -1.49 and a beta of 0.58.
VIVUS (NASDAQ:VVUS) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.08). The company had revenue of $14.96 million for the quarter. As a group, analysts forecast that VIVUS will post -4.4 EPS for the current year.
An institutional investor recently raised its position in VIVUS stock. Renaissance Technologies LLC lifted its stake in VIVUS, Inc. (NASDAQ:VVUS) by 5.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,273,800 shares of the biopharmaceutical company’s stock after purchasing an additional 423,100 shares during the period. Renaissance Technologies LLC owned 7.79% of VIVUS worth $5,833,000 as of its most recent SEC filing.
VIVUS Company Profile
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Featured Article: Fundamental Analysis
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.